	Office of Sponsor and Regulatory Oversight	Document #:	F06-301-S01
NIH NATIONAL CANCER INSTITUTE Center for Cancer Research	CCR Pregnancy Report and Follow-Up Form	Revision #:	2
	cent regnancy hepote and ronow op ronn	Effective Date:	28OCT2022

Ρ	rotocol	Number:
•	1010001	i tutti belli

Participant ID: ____ ___ ___ ___ ___ ___ ___

Instructions: When completing the form for the first time, fill in the requested information in Section A. Initial Report. Save the file prior to signing it so that the form is available if and when follow-up reports are made. Sign the Initial Report with a digital signature. Turn in the signed form to <u>OSROSafety@NIH.gov</u>.

When a follow-up report is made, open the unsigned form and complete Section B. Follow-Up Report. Save the file prior to signing it so that the form is available if and when additional follow-up reports are made. Sign the Follow-Up Report with a digital signature. Turn in the signed form to <u>OSROSafety@NIH.gov</u>.

Pregnancy has been reported under the protocol:	No	Yes

A. Initial Report

Date of initial report:

Pregnancy-related Information	1
--------------------------------------	---

Indicate the source of information: (may check Yes to more than one)

Pregnant person:	No	Yes
Family member:	No	Yes
Physician/medical chart:	No	Yes
Other:	No	Yes, specify:

Indicate who was pregnant or if pregnancy was suspected:

Pregnancy of participant

Pregnancy of participant's partner

Suspected pregnancy

	Office of Sponsor and Regulatory Oversight	Document #: F06-301-S01
NIH NATIONAL CANCER INSTITUTE Center for Cancer Research	r Cancer Research	Revision #: 2
	CCR Pregnancy Report and Follow-Up Form	

Т

Protocol Number: _____

Participant ID: ____ ___ ___ ___ ___ ___

Study Interventions

List all study interventions that are part of the IND, and commercial products being used to test the research hypothesis:

Study Intervention	Diagnosis for Use
Actual Dose Given Prior to SAE	Route
First Dose	Frequency
Last Dose (prior to SAE)	Action Taken
Study Intervention	Diagnosis for Use
Actual Dose Given Prior to SAE	Route
First Dose	Frequency
Last Dose (prior to SAE)	Action Taken
Study Intervention	Diagnosis for Use
Study Intervention Actual Dose Given Prior to SAE	Diagnosis for Use
Actual Dose Given Prior to SAE	Route
Actual Dose Given Prior to SAE	Route Frequency
Actual Dose Given Prior to SAE First Dose Last Dose (prior to SAE)	Route Frequency Action Taken
Actual Dose Given Prior to SAE First Dose Last Dose (prior to SAE) Study Intervention	Route Frequency Action Taken Diagnosis for Use

Click button below to add another Study Interventions page.

		0	ffice of Sponsor an	d Regulatory Oversight	Document #:	F06-301-S01
NIH Center for Can		CCE	Pregnancy Renor	t and Follow-Up Form	Revision #:	2
		cer			Effective Date:	28OCT2022
tocol Number:				Participant ID:		
Current Pregnancy Inform	mation					
Number of fetuses:						
Date of last menstrual pe	eriod:			(dd/MMM/yyyy)		
Estimated delivery date:				(dd/MMM/yyyy)		
How was estimated deliv	ery date determine	d?	Last menstrua Ultrasound	ll period		
If ultrasound, estima	ted date of exam:			(dd/MMM/yyyy)		
Height:	Date of height:			Height units:	Height:	
0		(dd/	МММ/уууу)	Inches		_
	Exact date			Centimeters		_
	Day unknov Day and mo		lown			
	Day, month					
Pre-pregnancy weight:	Date of pre-preg	nancy we	vight [.]	Weight units:	Weight:	
The pregnancy weight.			МММ/уууу)	Pounds	Weight.	
	Exact date			Kilograms		
	Day unknov			Kilograms		
	Day and mo Day, month					
	buy, mont	, and yee				
Previous Pregnancy Info	rmation					
Gravida (total number of	pregnancies includ	ing the cu	irrent pregnancy):	Ur	nknown	
Excluding the current pre	gnancy, provide nui	nbers for	the following (rec	ord "0" if none):		
Para events		-				
Live births:				Ur	nknown	
Extremely preterm (EPT) births (< 25 we	eks):		Ur	nknown	
Very preterm (VPT) k):	 Ur	nknown	
Early preterm births	•	-			nknown	
Late preterm births (nknown	
Early term births (37					nknown	
Full term births (39 0					nknown	

Unknown

Unknown

Post term births (\geq 42 0/7 weeks):

Late term births (41 0/7 – 41 6/7 weeks):

	Office of Sponsor and Regulatory Oversight	Document #:	F06-301-S01
NIH NATIONAL CANCER INSTITUTE Center for Cancer Research		Revision #:	2
		Effective Date:	28OCT2022

Prot	cocol Number:	Participant ID:			
	Previous Pregnancy Information				
	Stillbirths (≥ 20 weeks):		Unknown		
	Spontaneous miscarriages (< 20 weeks):		Unknown		
	Therapeutic abortions:		Unknown		
	Therapeutic abortions are defined as abortions due to medical reasons f	or the mother or f	etus.		
	Any major congenital anomalies with a previous pregnancy?	No	Yes	Unknown	

If yes, specify:

B. Follow-Up Information

Pregnancy Follow-Up	(Update as ap	plicable during follow-up)
Was follow-up contact made with the individual during the pregnancy?	No	Yes
If yes, list dates that contact was made, and update the other sections of this form, as necessary.		

#	Date	#	Date	#	Date
1		5		9	
2		6		10	
3		7		11	
4		8		12	

Pregnancy Status

(Update as applicable during follow-up)

Pregnancy status:

Pregnancy ongoing

Outcome known

Outcome unknown (participant lost to follow-up or refused to provide further information)

For known pregnancy outcomes, record pregnancy outcome data for each fetus using F07-301-S01 CCR Pregnancy Outcome Form.

NIH NATIONAL CANCER INSTITUTE Center for Cancer Research	Office of Sponsor and Regulatory Oversight	Document #:	F06-301-S01
	CCR Pregnancy Report and Follow-Up Form	Revision #:	2
		Effective Date:	28OCT2022

Protocol Number: _____

Participant ID: ____ ___ ___ ___ ___ ___

Т

Current Pregnancy Information Did the individual experience any of the complications listed below during this pregnancy?		(Update as applicable during follow-up)		
		No	Yes	Unknowr
If yes, report Adverse Event/Serio	pus Adverse, as appropriate.			
Abruptio placentae	Eclampsia	Oligohydramnios		
Abnormal bleeding/hemorrhage	Endometritis	Placenta previa		
Anaphylaxis	Fetal distress	Polyhydramnios		
Bacteremia	Fever > 100.4°F or 38.0°C	Pre-eclampsia		
Chorioamnionitis	Gestational diabetes	Pregnancy induced hypertension		
Coagulation disorders	GBS-positive	Preterm labor		
Did the individual experience any other complications during this pregnancy? If yes, document the event per CCR requirements, as appropriate.		No	Yes	Unknowr
Pregnancy Risk Factors		(Update as applicable during follow-up)		
Did the individual use tobacco products, drink alcohol, or use other illicit drugs during this pregnancy?		No	Yes	Unknown
Did the individual take any medications (over the counter and/or prescription) during the pregnancy?		No	Yes	Unknowr

If yes, document on the Concomitant Medications List.

Comments:

Signature: